Furthermore, when focusing on the early interruption of the OCEANIC-AF study with asundexian due to its low efficacy, as compared to the early interruption of the AZALEA-TIMI 71 trial with abelacimab for its superior safety with possible maintained efficacy, it could be speculated that a more intense and persistent inhibition of FXI occurs with abelacimab, due to its relatively long half-life, while oscillations over time in the extent of FXI inhibition might occur with small molecules, due to their shorter half-life. Here, F11 is linked to atrial fibrillation.